Stock CARDIUM THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Cardium Therapeutics Inc Nyse

Equities

US1419161062

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Cardium Therapeutics Inc
2022 Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
2021 Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
AQ
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)
AQ
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
AQ
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Cardium Therapeutics : Angionetics To Present At Marcum 2017 MicroCap conference In New York City
PU
Cardium Therapeutics : Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, China
PU
Cardium Therapeutics : Angionetics To Present At The Biotechnology Industry Organization CEO & Investor Conference At The Waldorf Astoria New York City
PU
Cardium Therapeutics : FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
PU
Cardium Therapeutics : Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
PU
Cardium Therapeutics : Angionetics' Generx® Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
PU
Cardium Therapeutics : Angionetics & A Huapont Life Sciences Affiliate Enter Agreement To Commercialize Generx® Angiogenic Gene Therapy Product Candidate For Ischemic Heart Disease In China
PU
Cardium Therapeutics : Angionetics & A Huapont Life Sciences (China) Affiliate Enter Into Equity Financing Agreement For Phase 3 Clinical Development Of Generx Gene Therapy For Ischemic Heart Disease
PU
Cardium Therapeutics : Angionetics To Present At 2015 LD Micro Invitational Investor Conference On Business And Generx® Phase 3 Clinical Development Activities
PU
Cardium Therapeutics : Angionetics Presents at the 2015 American Society of Gene & Cell Therapy Conference On Generx® Angiogenic Phase 3 Gene Therapy Program
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRXM Stock
  4. Stock
  5. News Cardium Therapeutics Inc
  6. Press Releases